- Previous Close
10.45 - Open
10.45 - Bid 10.35 x --
- Ask 10.60 x --
- Day's Range
10.35 - 10.80 - 52 Week Range
8.96 - 16.40 - Volume
73,816 - Avg. Volume
159,138 - Market Cap (intraday)
986.505M - Beta (5Y Monthly) 0.38
- PE Ratio (TTM)
-- - EPS (TTM)
-1.79 - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
TWi Biotechnology, Inc., a clinical-stage biopharmaceutical company, develops and sells drugs for innate immunity-related diseases in Taiwan. The company development pipeline comprises AC-203, which is in Phase 2 clinical trial for various indications, including epidermolysis bullosa simplex, epidermolysis bullosa, arthritis, gout, and diabetes mellitus; and AC- 1101, which is in Phase 1 trial for the treatment of vitiligo and preclinical stage for the treatment of atopic dermatitis, as well as granuloma annulare and rare autoimmune skin diseases. It has a drug development agreement with Hong Kong Winhealth Pharma Group Co., Limited. in Mainland China, Hong Kong, and Macao markets. TWi Biotechnology, Inc. was founded in 2010 and is based in Taipei, Taiwan.
www.twibiotech.comRecent News: 6610.TWO
View MorePerformance Overview: 6610.TWO
Trailing total returns as of 4/16/2025, which may include dividends or other distributions. Benchmark is TSEC CAPITALIZATION WEIGHTED ST (^TWII) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: 6610.TWO
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: 6610.TWO
View MoreValuation Measures
Market Cap
963.46M
Enterprise Value
803.46M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
5.48
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-59.15%
Return on Equity (ttm)
-110.80%
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-226.53M
Diluted EPS (ttm)
-1.79
Balance Sheet and Cash Flow
Total Cash (mrq)
230.42M
Total Debt/Equity (mrq)
2.84%
Levered Free Cash Flow (ttm)
-105.96M